Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXIT-BT2
NCT06010628Phase 4Recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Feb 2024
- Primary completion
- Dec 2029
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 4 trial of tenecteplase in ischemic stroke, sponsored by General Hospital of the Northern Theater Command. Started Feb 2024; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06010628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06010628.